Clinical Trial Update: Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating submucosal bevacizumab for recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 2 | Status: COMPLETED | Results posted: 2019-12-04